LCN2 and COVID-19: At maximum extent of ATI (>50% of tubules), KIM-1 was expressed in 27% (3322 of 12,123), whereas NGAL was expressed in 65.7% (6580 of 10,111) of the tubules, including significant coexpression with KIM-1 in 85% of COVID-19 kidneys and with proximal marker LRP2 in 77% of the kidneys (Figure 2d and e).